This article is more than 5 years old. Information may no longer be current.

NovaTears available in Australia

Issue: July 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NovaTears topical treatment for dry eye disease and meibomian gland dysfunction is now available in Australia, Novaliq announced in a press release.

AFT Pharmaceuticals, a New Zealand-based pharmaceutical company, is commercializing the product throughout Australia and New Zealand, where it was launched 8 months ago, the release said.

“With the introduction of NovaTears, dry eye sufferers in Australia now have a new and highly efficacious treatment option that provides significant improvement to the signs and symptoms of evaporative DED,” Christian Roesky, PhD, managing director and CEO of Novaliq, said in the release.